Park Ave Peptides — Clinical Reference Library — For Professional Use Only

Mitochondrial Medicine · Cardiology Research
Reference Compound
SS-31 (elamipretide; Bendavia) is a cell-permeable Szeto-Schiller tetrapeptide that selectively targets the inner mitochondrial membrane. The peptide binds cardiolipin — a phospholipid uniquely concentrated in the inner mitochondrial membrane — with high affinity, anchoring the compound at the site of the electron transport chain.
At a Glance
Quality Documentation
Lot PAP-SS31EL-240118-A01 — Reference
Field of Medicine — Mitochondrial Medicine · Cardiology Research
Mitochondrial Medicine and Cardiology Research.
SS-31 (elamipretide) is a synthetic tetrapeptide (D-Arg-2,6-dimethylTyr-Lys-Phe-NH2) designed to selectively target the inner mitochondrial membrane. It is one of the most advanced mitochondria-targeted therapeutics in clinical development.
SS-31 binds with high affinity to cardiolipin in the inner mitochondrial membrane, stabilizing cristae architecture, optimizing electron-transport chain efficiency, and reducing reactive-oxygen-species generation. It does not act as a free-radical scavenger in cytoplasmic compartments.
Reference Compound
SS-31 (Elamipretide)
02 — Science
03 — Pathway
Pathway Summary
SS-31 (elamipretide; Bendavia) is a cell-permeable Szeto-Schiller tetrapeptide that selectively targets the inner mitochondrial membrane. The peptide binds cardiolipin — a phospholipid uniquely concentrated in the inner mitochondrial membrane — with high affinity, anchoring the compound at the site of the electron transport chain.
SS-31 (elamipretide; Bendavia) is a cell-permeable Szeto-Schiller tetrapeptide that selectively targets the inner mitochondrial membrane. The peptide binds cardiolipin — a phospholipid uniquely concentrated in the inner mitochondrial membrane — with high affinity, anchoring the compound at the site of the electron transport chain.
Cardiolipin binding stabilizes the supercomplex organization of respiratory chain Complexes I, III, and IV, improves electron transport coupling, reduces electron leak, and decreases mitochondrial reactive oxygen species generation. The functional consequence in preclinical models is improved ATP production, preserved mitochondrial cristae structure, and reduced oxidative stress.
Clinical development has focused on primary mitochondrial myopathies, ischemia-reperfusion injury, and age-related muscle and ocular disorders. The compound is an extensively studied tool in mitochondrial bioenergetics research.
04 — Lab Reference
For licensed research and clinical evaluation only. Not dosing guidance.
Reconstitution
Bacteriostatic water (0.9% benzyl alcohol) or sterile water. Add diluent slowly along the vial wall — do not inject directly onto the lyophilized cake. Swirl gently until fully dissolved.
Storage
Lyophilized: −20°C long term; 2–8°C short term (weeks). Protect from light.Reconstituted: 2–8°C, generally up to 14–28 days depending on compound.
Quality
≥99% purity by HPLC. Identity confirmed by mass spectrometry. Independent third-party verification on every lot. COA available per lot.
Handling notes —Avoid repeated freeze–thaw cycles. Do not shake vigorously after reconstitution.
Need a full protocol brief?
Reconstitution worksheets, concentration reference cards, and sample COA for verified accounts.
05 — Comparative
See molecular profile, pharmacokinetics, and handling next to related compounds in the same family.
06 — Citations
The following sources are representative of the literature describing SS-31 (Elamipretide). A full annotated citation list with PubMed identifiers is available on request.
See also the glossary of research terms and the full peptide library.
cGMP facility · Third-party tested · Cold-chain shipping · 24-hour COA on request